NLSDays

AlzeCure Pharma's project NeuroRestore ACD856 has received EUR 2.5 million from the EU's European Innovation Council.

The Finnish biotech company developing stem cell therapies for vision restoration, has raised funding from Voima Ventures, Finnish family offices (Stephen Industries Inc. & Biothom Oy), private investors, and Business Finland.

The decision is in line with Aqilion's strategy to focus the business to the internal pipeline programs within chronic inflammation.

The Gates Foundation, Novo Nordisk Foundation, and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a USD 50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Abera Bioscience reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results in the mouse model.

All participants are determined to establish Europe as a global leader in Artificial Intelligence (AI), advancing AI development and application.